Synonyms: NYX2925
Compound class:
Synthetic organic
Comment: NYX-2925 is a oral, brain-penetrating, NMDA receptor modulator that was developed by Aptinyx [2]. It acts as a co-agonist to glutamate and partially activates NMDARs. NYX-2925 is being investigated for potential to modulate neural pathways relevant for chronic pain.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Houck DR, Sindelar L, Sanabria CR, Stanworth SH, Krueger M, Suh M, Madsen TM. (2019)
NYX-2925, A Novel N-methyl-D-aspartate Receptor Modulator: A First-in-Human, Randomized, Double-blind Study of Safety and Pharmacokinetics in Adults. Clin Transl Sci, 12 (2): 164-171. [PMID:30242962] |
2. Khan MA, Houck DR, Gross AL, Zhang XL, Cearley C, Madsen TM, Kroes RA, Stanton PK, Burgdorf J, Moskal JR. (2018)
NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. Int J Neuropsychopharmacol, 21 (3): 242-254. [PMID:29099938] |